They tried to recruit one of my acquaintances to work for for them in sales or something of that nature. The pay would have been decent but the company was "creepy as fuck" as my acquaintance put it.
A startup company, Ambrosia, has been selling "young blood transfusions" for $8,000 since 2016 under the guise of running a clinical trial, to see if such transfusions lead to changes in the blood of recipients.[1][14] As of August 2017, they had 600 people join.[15] The clinical trial has no control arm and so is neither randomized nor blind. As described, whole blood collected by blood banks that had passed its 42-day storage limit was centrifuged to remove cells, the resulting cell-free plasma pooled from several donations and intravenously transfused into recipients.[15] The company was started by Jesse Karmazin, a medical school graduate without a license to practice medicine.[16] David Wright is the licensed doctor overseeing the clinical trial; in his practice he administers intravenous treatments of vitamins and antibiotics for nontraditional purposes and was disciplined by the California Medical Board for the latter in 2015. Jonathan Kimmelman, a bioethicist from McGill University, suggests that Ambrosia is running this as a trial as they would be unable to get FDA approval to sell this treatment otherwise.
Source: https://en.wikipedia.org/wiki/Young_blood_transfusion#Ambros...
How often does this happened? I am continually being spammed by Stanford saying they have a critical shortage, and I do almost the maximum number of donations a year. I would hate to discover that it's all a waste.
Don’t try catching up on your sleep while doing this because they get upset thinking you passed out.
Seems a worthy way to make money to me.
I'm also glad there are people willing to take some calculated risks so we can continue to learn about ourselves and our world.
1. Gathering accurate data
2. Sharing (or intending to share) the accurate data
This seems like a great business? Blood banks get to monetize what would have otherwise been a waste product. And we get more data. Why is it creepier than standard organ donation?
There isn't really an experiment being run, just the waste product --> money pipeline.
You're claiming we have all the clinical data we need on this treatment model?
That's very charitable.
If you need a transfusion, the risk doesn't matter, but to willingly do it is really foolish.